Key Takeaways
- Cardinal Health elevated its fiscal-year adjusted EPS forecast to $10.70โ$10.80, an increase from the previous $10.15โ$10.35 range.
- Third-quarter adjusted EPS reached $3.17, surpassing the Wall Street consensus of $2.79.
- Total revenue increased 11% to $60.9 billion but fell short of the $62.1 billion analyst estimate.
- Net income declined to $399 million from $506 million year-over-year, impacted by a $184 million goodwill impairment.
- CAH stock advanced 1.6% during premarket hours on Thursday.
Cardinal Health has upgraded its annual profit projection for the second consecutive time this fiscal year, catching Wall Street’s attention. Shares jumped 1.6% in Thursday’s premarket session, trading at $205.99.
The healthcare distributor now anticipates adjusted earnings between $10.70 and $10.80 per share for fiscal 2026. This represents a notable improvement from the February outlook of $10.15 to $10.35. The Street had been modeling approximately $10.31 per share.
The elevated guidance provided significant momentum for the stock. However, the quarterly performance itself presented a more complicated picture.
Adjusted earnings per share landed at $3.17, significantly exceeding the $2.79 Wall Street forecast. This substantial beat captured investor attention.
Revenue numbers, however, presented a contrasting narrative. Overall sales climbed 11% on a year-over-year basis to $60.9 billion, yet this figure lagged the $62.1 billion analyst consensus.
The pharmaceutical and specialty solutions division accounted for the majority of growth, generating $56.1 billion in revenueโan 11% increase compared to the prior-year period.
The global medical products and distribution division proved less robust. Revenue in this segment remained essentially unchanged from last year, hampered by reduced distribution volumes.
Bottom Line Under Pressure
Net income fell to $399 million from $506 million in the comparable quarter last year. The decline stemmed primarily from a $184 million pretax goodwill impairment charge.
This charge related to Cardinal’s oncology practice alliance and its Integrated Oncology Network, an asset the company purchased in late 2024.
While goodwill impairments don’t represent actual cash outflows, they indicate that an acquired business isn’t delivering the value anticipated at acquisition. Such charges warrant attention.
Evercore ISI analyst Elizabeth Anderson characterized the performance as “solid,” explaining that the pharmaceutical revenue shortfall stemmed mainly from wholesale acquisition cost dynamicsโa passthrough matter rather than a core operational weakness.
Specialty Pharmaceutical Growth Drives Optimism
Cardinal Health, alongside industry peers Cencora and McKesson, continues benefiting from robust demand for high-margin specialty pharmaceuticals. Medications addressing cancer and autoimmune conditions represent an expanding portion of the distribution landscape.
Biosimilar introductions for patent-expired blockbuster medications are also contributing to volume growth. These segments allow distributors to capture superior margins compared to traditional generic pharmaceuticals.
Cardinal has been broadening its specialty care presence through strategic acquisitions of physician practices and specialty networks. The Integrated Oncology Network transaction exemplified this strategic direction.
This approach hasn’t proceeded without challengesโthis quarter’s impairment charge demonstrates that reality. Nevertheless, management remains committed to the overall strategy.
The second consecutive quarterly guidance increase signals management confidence in performance during the remainder of the fiscal year.
Cardinal Health’s fiscal third quarter concluded on March 31. The stock traded 1.6% higher in premarket activity at $205.99 at publication time.
